Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine

PLoS One. 2017 Apr 14;12(4):e0175369. doi: 10.1371/journal.pone.0175369. eCollection 2017.

Abstract

Astrocytes play critical roles in central nervous system homeostasis and support of neuronal function. A better knowledge of their response may both help understand the pathophysiology of Alzheimer's disease (AD) and implement new therapeutic strategies. We used the 5xFAD transgenic mouse model of AD (Tg thereafter) to generate astrocyte cultures and investigate the impact of the genotype on metabolic changes and astrocytes activation. Metabolomic analysis showed that Tg astrocytes exhibited changes in the glycolytic pathway and tricarboxylic acid (TCA) cycle, compared to wild type (WT) cells. Tg astrocytes displayed also a prominent basal inflammatory status, with accentuated reactivity and increased expression of the inflammatory cytokine interleukin-1 beta (IL-1β). Compensatory mechanisms were activated in Tg astrocytes, including: i) the hexose monophosphate shunt with the consequent production of reducing species; ii) the induction of hypoxia inducible factor-1 alpha (HIF-1α), known to protect against amyloid-β (Aβ) toxicity. Such events were associated with the expression by Tg astrocytes of human isoforms of both amyloid precursor protein (APP) and presenilin-1 (PS1). Similar metabolic and inflammatory changes were induced in WT astrocytes by exogenous Aβ peptide. Pantethine, the vitamin B5 precursor, known to be neuroprotective and anti-inflammatory, alleviated the pathological pattern in Tg astrocytes as well as WT astrocytes treated with Aß. In conclusion, our data enlighten the dual pathogenic/protective role of astrocytes in AD pathology and the potential protective role of pantethine.

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology*
  • Amyloid beta-Protein Precursor / genetics
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Astrocytes / cytology
  • Astrocytes / drug effects*
  • Astrocytes / pathology*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Citric Acid Cycle / drug effects
  • Disease Models, Animal
  • Gene Expression / drug effects
  • Glycolysis / drug effects
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Inflammation* / drug therapy
  • Inflammation* / pathology
  • Interleukin-1beta / analysis
  • Interleukin-1beta / metabolism
  • Metabolomics
  • Mice
  • Mice, Transgenic
  • Pantetheine / analogs & derivatives*
  • Pantetheine / pharmacology
  • Pantetheine / therapeutic use
  • Pentose Phosphate Pathway / drug effects
  • Presenilin-1 / genetics
  • Presenilin-1 / metabolism
  • RNA, Messenger / metabolism

Substances

  • Amyloid beta-Protein Precursor
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Interleukin-1beta
  • Presenilin-1
  • RNA, Messenger
  • Pantetheine
  • pantethine

Grants and funding

Support was provided by: CNRS and Aix-Marseille université (MvGB, BG, MK, SR, KB, PB); ANR-11-MALZ-0007 (MK), ANR-15-CE16-0006 (SR) [www.agence-nationale-recherche.fr]; Fonds Européen de développement régional (FEDER in PACA) (MK, SR) [www.europe.regionpaca.fr]; DHUNE project supported by A*MIDEX (MK, SR) [www.dhune.org]; Association France Alzheimer (SR) [www.francealzheimer.org]; LECMA (MK, SR) [www.maladiealzheimer.fr]; Fondation Plan Alzheimer (KB) [www.fondation-alzheimer.org]; Post-doctoral support from the Management de talents (A*MIDEX) [www.amidex.univ-amu.fr]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.